mBio
(Jun 2021)
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
Takuya Tada,
Belinda M. Dcosta,
Marie I. Samanovic,
Ramin S. Herati,
Amber Cornelius,
Hao Zhou,
Ada Vaill,
Wes Kazmierski,
Mark J. Mulligan,
Nathaniel R. Landau
Affiliations
Takuya Tada
Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA
Belinda M. Dcosta
Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA
Marie I. Samanovic
NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, New York, USA
Ramin S. Herati
NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, New York, USA
Amber Cornelius
NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, New York, USA
Hao Zhou
Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA
Ada Vaill
Biohaven Pharmaceuticals, Inc., New Haven, Connecticut, USA
Wes Kazmierski
Biohaven Pharmaceuticals, Inc., New Haven, Connecticut, USA
Mark J. Mulligan
NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, New York, USA
Nathaniel R. Landau
ORCiD Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA
DOI
https://doi.org/10.1128/mBio.00696-21
Journal volume & issue
Vol. 12,
no. 3
Abstract
Read online
The rapid evolution of SARS-CoV-2 variants has raised concerns with regard to their potential to escape from vaccine-elicited antibodies and anti-spike protein monoclonal antibodies. We report here on an analysis of sera from recovered patients and vaccinated individuals and on neutralization by Regeneron therapeutic monoclonal antibodies.
WeChat QR code
Close
